Imran Eba
Partner, Action Potential Venture Capital

Imran is a founding partner at Action Potential Venture Capital, GSK’s corporate venture capital fund focused on investing in companies that pioneer bioelectronic medicines and other whitespace non-drug therapies. Imran represents Action Potential as a board member in NeuSpera Medical, SetPoint Medical, Axon Therapies and Alpheus Medical. Imran is also a founding member and program advisor to the Harvard Healthtech Fellowship which aims to bring together innovators from the fields of engineering, technology and medicine to discover and develop novel non-drug therapies with the vision of making Boston a powerhouse in this field as it has been in biotech. Imran is based in Cambridge, MA.

Juan-Pablo Mas, MBA
Partner, Action Potential Venture Capital

Juan-Pablo Mas is a Partner at Action Potential VC, a bioelectronic medicine fund founded by GlaxoSmithKline, and is based in Santa Cruz, CA. He represents APVC on the Boards of Cala Health, CVRx, Exo Imaging, Neuspera Medical, Presidio Medical, Saluda Medical, and SetPoint Medical. He was previously an investor at Lightstone Ventures and Morgenthaler Ventures, where he was a Board observer at Ardian, Twelve, Nuvaira, Cabochon, and Miramar Labs. Prior to investing, Juan-Pablo led R&D and Strategy teams in Medtronic’s CardioVascular Division and was a member of the Global Brand Strategy team at Eli Lilly. Juan-Pablo earned an MBA from the Stanford Graduate School of Business as a Bonini Fellow, an MS in Electrical Engineering from Stanford University, and a BS in EE from the University of Massachusetts. He now serves on the Oversight Committee for Stanford’s Wu Tsai Neuroscience Institute, the Advisory Board for UCSF’s Rosenman Institute, and is a co-founder of LatinxVC which is dedicated to increasing diversity within venture capital.

Jordi Parramon, PhD
President, Medical Devices, Verily

Jordi leads Verily's medical devices business, combining hardware with software and machine learning to create differentiated product solutions that support Verily's research and health platforms, as well as external partnerships and joint ventures. Areas of interest include wearable monitoring sensors, diagnostics, surgical robotics, bioelectronics, ophthalmology and drug delivery devices. Jordi has more than 20 years of experience in the Medical Devices industry including a 12-year tenure at Boston Scientific before joining Verily. Jordi has authored more than 60 distinct patent families with 200+ granted patents worldwide. He holds a BS degree in Physics from the Universitat Autònoma de Barcelona and BS, MS and PhD degrees in Electrical Engineering from the National Center for Microelectronics of Spain at the Universitat Autònoma de Barcelona.

Paul Peter Tak, MD, PhD
President & CEO, Candel Therapeutics

Paul Peter Tak is currently President & CEO of Candel Therapeutics. He received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He served as Professor of Medicine and founding Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC). His scientific work in academia includes the discovery of the cholinergic anti-inflammatory pathway (inflammatory reflex) in chronic inflammation, and pioneered vagus nerve stimulation in rheumatoid arthritis patients. Paul has published extensively in peer-reviewed journals (>570 publications, H-index 131, >75,000 citations). He received the Medal of Honour from the Netherlands Society for Rheumatology, was elected ‘Best Rheumatologist’ in the Netherlands, was awarded Honorary Membership by EULAR and has been elected Fellow of the Academy of Medical Sciences in the U.K. Before becoming President & CEO of Candel Therapeutics, he had previously been a business leader at GlaxoSmithKline and Flagship Pioneering as well as board director of various companies including Galvani Bioelectronics.

Kate Rosenbluth, PhD
Founder & CSO, Cala Health

Kate Rosenbluth is the Founder of Cala Health, a bioelectronic medicines company transforming the standard of care for chronic disease. The company's wearable neuromodulation therapies merge innovations in neuroscience and technology. Prior to spinning Cala out from the Stanford Biodesign fellowship, she developed cutting-edge neurotherapies with Brainlab, Autonomic Technologies, and Genentech, and completed a Postdoctoral Fellowship at UCSF in Neurosurgery following her PhD in Bioengineering at UC Berkeley and UCSF. Kate has authored more than 60 patents and peer-reviewed publications. She is a perpetual student and committed educator in innovation leadership and healthcare. Kate currently serves on the McKinsey Women’s Executive Roundtable and the Strategy Group of the Center for Healthcare Innovation.

Michael Ackermann, PhD
CEO, Presidio Medical

Michael is CEO of neuromodulation company Presidio Medical. Michael also serves as Chairman of Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS). He was previously Chairman of Oyster Point Pharma, Inc. (NASDAQ: OYST), and Vice President, Neurostimulation for Allergan, plc after serving as CEO of Oculeve, Inc., which was acquired by Allergan. He received a BE degree in biomedical engineering from Vanderbilt University, MS and PhD degrees in biomedical engineering from Case Western Reserve University, is a graduate of the Stanford University Biodesign Fellowship and Vision Research Fellowship at Stanford University. He has numerous patents and peer-reviewed publications.